#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Cholesterol is predominantly synthesized de novo in the liver with lesser amounts obtained from the diet .
2-1	16-27	Cholesterol	substance	new	coref	4-12
2-2	28-30	is	_	_	_	_
2-3	31-44	predominantly	_	_	_	_
2-4	45-56	synthesized	_	_	_	_
2-5	57-59	de	_	_	_	_
2-6	60-64	novo	_	_	_	_
2-7	65-67	in	_	_	_	_
2-8	68-71	the	object[3]	new[3]	coref	4-27[0_3]
2-9	72-77	liver	object[3]	new[3]	_	_
2-10	78-82	with	_	_	_	_
2-11	83-89	lesser	substance[4]	new[4]	_	_
2-12	90-97	amounts	substance[4]	new[4]	_	_
2-13	98-106	obtained	substance[4]	new[4]	_	_
2-14	107-111	from	substance[4]	new[4]	_	_
2-15	112-115	the	substance[4]|substance[5]	new[4]|new[5]	_	_
2-16	116-120	diet	substance[4]|substance[5]	new[4]|new[5]	_	_
2-17	121-122	.	_	_	_	_

#Text=Dietary intake , de novo synthesis , metabolism and excretion , combine to balance circulating cholesterol levels ensuring extra-hepatic tissues are sufficiently equipped to produce a range of metabolites including steroid hormones , bile acids and seco-steroids .
3-1	123-130	Dietary	event[6]	new[6]	_	_
3-2	131-137	intake	event[6]	new[6]	_	_
3-3	138-139	,	_	_	_	_
3-4	140-142	de	abstract[7]	new[7]	_	_
3-5	143-147	novo	abstract[7]	new[7]	_	_
3-6	148-157	synthesis	abstract[7]	new[7]	_	_
3-7	158-159	,	_	_	_	_
3-8	160-170	metabolism	abstract	new	coref	5-8[44_0]
3-9	171-174	and	_	_	_	_
3-10	175-184	excretion	event	new	_	_
3-11	185-186	,	_	_	_	_
3-12	187-194	combine	_	_	_	_
3-13	195-197	to	_	_	_	_
3-14	198-205	balance	_	_	_	_
3-15	206-217	circulating	abstract[10]	new[10]	_	_
3-16	218-229	cholesterol	abstract[10]	new[10]	_	_
3-17	230-236	levels	abstract[10]	new[10]	_	_
3-18	237-245	ensuring	_	_	_	_
3-19	246-259	extra-hepatic	object[11]	new[11]	coref	7-20[0_11]
3-20	260-267	tissues	object[11]	new[11]	_	_
3-21	268-271	are	_	_	_	_
3-22	272-284	sufficiently	_	_	_	_
3-23	285-293	equipped	_	_	_	_
3-24	294-296	to	_	_	_	_
3-25	297-304	produce	_	_	_	_
3-26	305-306	a	_	_	_	_
3-27	307-312	range	_	_	_	_
3-28	313-315	of	_	_	_	_
3-29	316-327	metabolites	substance[12]	new[12]	_	_
3-30	328-337	including	substance[12]	new[12]	_	_
3-31	338-345	steroid	substance[12]|object|substance[14]	new[12]|new|new[14]	_	_
3-32	346-354	hormones	substance[12]|substance[14]	new[12]|new[14]	_	_
3-33	355-356	,	substance[12]	new[12]	_	_
3-34	357-361	bile	substance[12]|object|substance[16]	new[12]|new|new[16]	coref	13-47[126_16]
3-35	362-367	acids	substance[12]|substance[16]	new[12]|new[16]	_	_
3-36	368-371	and	substance[12]	new[12]	_	_
3-37	372-385	seco-steroids	substance[12]|substance	new[12]|new	_	_
3-38	386-387	.	_	_	_	_

#Text=Side-chain hydroxycholesterols ( scOHCs ) are typically formed through hydroxylation of cholesterol by specialized members of the Cytochrome P450 family , which bind and activate the Liver X Receptor-alpha ( LXRA ; gene name NR1H3 ) and beta ( LXRB ; gene name NR1H2 ) transcription factors .
4-1	388-398	Side-chain	substance[18]	new[18]	_	_
4-2	399-418	hydroxycholesterols	substance[18]	new[18]	_	_
4-3	419-420	(	_	_	_	_
4-4	421-427	scOHCs	abstract	new	coref	7-15[59_0]
4-5	428-429	)	_	_	_	_
4-6	430-433	are	_	_	_	_
4-7	434-443	typically	_	_	_	_
4-8	444-450	formed	_	_	_	_
4-9	451-458	through	_	_	_	_
4-10	459-472	hydroxylation	abstract[20]	new[20]	_	_
4-11	473-475	of	abstract[20]	new[20]	_	_
4-12	476-487	cholesterol	abstract[20]|substance	new[20]|giv	coref	5-8
4-13	488-490	by	_	_	_	_
4-14	491-502	specialized	animal[22]	new[22]	_	_
4-15	503-510	members	animal[22]	new[22]	_	_
4-16	511-513	of	animal[22]	new[22]	_	_
4-17	514-517	the	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-18	518-528	Cytochrome	animal[22]|abstract|abstract[25]	new[22]|new|new[25]	_	_
4-19	529-533	P450	animal[22]|time|abstract[25]	new[22]|new|new[25]	_	_
4-20	534-540	family	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-21	541-542	,	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-22	543-548	which	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-23	549-553	bind	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-24	554-557	and	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-25	558-566	activate	animal[22]|abstract[25]	new[22]|new[25]	_	_
4-26	567-570	the	animal[22]|abstract[25]|abstract[28]|abstract[39]	new[22]|new[25]|new[28]|new[39]	appos	4-31[0_28]
4-27	571-576	Liver	animal[22]|abstract[25]|object|abstract[28]|abstract[39]	new[22]|new[25]|giv|new[28]|new[39]	coref	6-11[48_0]
4-28	577-578	X	animal[22]|abstract[25]|person|abstract[28]|abstract[39]	new[22]|new[25]|new|new[28]|new[39]	_	_
4-29	579-593	Receptor-alpha	animal[22]|abstract[25]|abstract[28]|abstract[39]	new[22]|new[25]|new[28]|new[39]	_	_
4-30	594-595	(	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-31	596-600	LXRA	animal[22]|abstract[25]|abstract|abstract[39]	new[22]|new[25]|giv|new[39]	appos	4-33[31_0]
4-32	601-602	;	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-33	603-607	gene	animal[22]|abstract[25]|abstract|abstract[31]|abstract[39]	new[22]|new[25]|new|giv[31]|new[39]	coref|appos	4-42|4-42[36_31]
4-34	608-612	name	animal[22]|abstract[25]|abstract[31]|abstract[39]	new[22]|new[25]|giv[31]|new[39]	_	_
4-35	613-618	NR1H3	animal[22]|abstract[25]|abstract[31]|abstract|abstract[39]	new[22]|new[25]|giv[31]|new|new[39]	_	_
4-36	619-620	)	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-37	621-624	and	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-38	625-629	beta	animal[22]|abstract[25]|abstract|abstract[39]	new[22]|new[25]|new|new[39]	appos	4-40
4-39	630-631	(	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-40	632-636	LXRB	animal[22]|abstract[25]|abstract|abstract[39]	new[22]|new[25]|giv|new[39]	coref	6-23
4-41	637-638	;	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-42	639-643	gene	animal[22]|abstract[25]|abstract|abstract[36]|abstract[39]	new[22]|new[25]|giv|giv[36]|new[39]	coref	6-7[0_36]
4-43	644-648	name	animal[22]|abstract[25]|abstract[36]|abstract[39]	new[22]|new[25]|giv[36]|new[39]	_	_
4-44	649-654	NR1H2	animal[22]|abstract[25]|abstract[36]|abstract|abstract[39]	new[22]|new[25]|giv[36]|new|new[39]	_	_
4-45	655-656	)	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-46	657-670	transcription	animal[22]|abstract[25]|abstract|abstract[39]	new[22]|new[25]|new|new[39]	coref	8-11[67_0]
4-47	671-678	factors	animal[22]|abstract[25]|abstract[39]	new[22]|new[25]|new[39]	_	_
4-48	679-680	.	_	_	_	_

#Text=LXR target genes are typically involved in cholesterol and fatty acid metabolism .
5-1	681-684	LXR	abstract|abstract[41]	new|new[41]	coref	9-22
5-2	685-691	target	abstract[41]	new[41]	_	_
5-3	692-697	genes	abstract[41]	new[41]	_	_
5-4	698-701	are	_	_	_	_
5-5	702-711	typically	_	_	_	_
5-6	712-720	involved	_	_	_	_
5-7	721-723	in	_	_	_	_
5-8	724-735	cholesterol	substance|abstract[44]	giv|giv[44]	coref|coref	23-41|23-41[230_44]
5-9	736-739	and	abstract[44]	giv[44]	_	_
5-10	740-745	fatty	substance[43]|abstract[44]	new[43]|giv[44]	_	_
5-11	746-750	acid	substance[43]|abstract[44]	new[43]|giv[44]	_	_
5-12	751-761	metabolism	abstract[44]	giv[44]	_	_
5-13	762-763	.	_	_	_	_

#Text=In normal tissue , expression of LXRA is inducible in the liver , intestine , macrophages and adipocytes , whilst expression of LXRB is more ubiquitous .
6-1	764-766	In	_	_	_	_
6-2	767-773	normal	object[45]	new[45]	coref	20-13[185_45]
6-3	774-780	tissue	object[45]	new[45]	_	_
6-4	781-782	,	_	_	_	_
6-5	783-793	expression	abstract[46]	new[46]	_	_
6-6	794-796	of	abstract[46]	new[46]	_	_
6-7	797-801	LXRA	abstract[46]|abstract	new[46]|giv	coref	7-8
6-8	802-804	is	_	_	_	_
6-9	805-814	inducible	_	_	_	_
6-10	815-817	in	_	_	_	_
6-11	818-821	the	object[48]	giv[48]	_	_
6-12	822-827	liver	object[48]	giv[48]	_	_
6-13	828-829	,	_	_	_	_
6-14	830-839	intestine	plant	new	_	_
6-15	840-841	,	_	_	_	_
6-16	842-853	macrophages	animal	new	_	_
6-17	854-857	and	_	_	_	_
6-18	858-868	adipocytes	animal	new	_	_
6-19	869-870	,	_	_	_	_
6-20	871-877	whilst	_	_	_	_
6-21	878-888	expression	abstract[52]	new[52]	_	_
6-22	889-891	of	abstract[52]	new[52]	_	_
6-23	892-896	LXRB	abstract[52]|abstract	new[52]|giv	coref	7-10
6-24	897-899	is	_	_	_	_
6-25	900-904	more	_	_	_	_
6-26	905-915	ubiquitous	_	_	_	_
6-27	916-917	.	_	_	_	_

#Text=As well as differences in expression of LXRA and LXRB , local concentrations of the scOHCs differ considerably between tissues , and relative to each other , sometimes by as much as 1000-fold and variance can also depend on disease status .
7-1	918-920	As	_	_	_	_
7-2	921-925	well	_	_	_	_
7-3	926-928	as	_	_	_	_
7-4	929-940	differences	abstract[54]	new[54]	_	_
7-5	941-943	in	abstract[54]	new[54]	_	_
7-6	944-954	expression	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-7	955-957	of	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-8	958-962	LXRA	abstract[54]|abstract[55]|abstract	new[54]|new[55]|giv	coref	13-1
7-9	963-966	and	abstract[54]|abstract[55]	new[54]|new[55]	_	_
7-10	967-971	LXRB	abstract[54]|abstract[55]|abstract	new[54]|new[55]|giv	coref	13-9
7-11	972-973	,	_	_	_	_
7-12	974-979	local	abstract[58]	new[58]	coref	10-8[79_58]
7-13	980-994	concentrations	abstract[58]	new[58]	_	_
7-14	995-997	of	abstract[58]	new[58]	_	_
7-15	998-1001	the	abstract[58]|abstract[59]	new[58]|giv[59]	coref	8-3[65_59]
7-16	1002-1008	scOHCs	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
7-17	1009-1015	differ	_	_	_	_
7-18	1016-1028	considerably	_	_	_	_
7-19	1029-1036	between	_	_	_	_
7-20	1037-1044	tissues	object	giv	_	_
7-21	1045-1046	,	_	_	_	_
7-22	1047-1050	and	_	_	_	_
7-23	1051-1059	relative	_	_	_	_
7-24	1060-1062	to	_	_	_	_
7-25	1063-1067	each	_	_	_	_
7-26	1068-1073	other	_	_	_	_
7-27	1074-1075	,	_	_	_	_
7-28	1076-1085	sometimes	_	_	_	_
7-29	1086-1088	by	_	_	_	_
7-30	1089-1091	as	_	_	_	_
7-31	1092-1096	much	_	_	_	_
7-32	1097-1099	as	_	_	_	_
7-33	1100-1109	1000-fold	object	new	_	_
7-34	1110-1113	and	_	_	_	_
7-35	1114-1122	variance	abstract	new	_	_
7-36	1123-1126	can	_	_	_	_
7-37	1127-1131	also	_	_	_	_
7-38	1132-1138	depend	_	_	_	_
7-39	1139-1141	on	_	_	_	_
7-40	1142-1149	disease	abstract|abstract[64]	new|new[64]	coref|coref	20-33[191_0]|23-11[221_64]
7-41	1150-1156	status	abstract[64]	new[64]	_	_
7-42	1157-1158	.	_	_	_	_

#Text=Furthermore , the different scOHCs have varying capacities to activate LXR-mediated transcription , imposing an element of selective modulation onto signalling .
8-1	1159-1170	Furthermore	_	_	_	_
8-2	1171-1172	,	_	_	_	_
8-3	1173-1176	the	abstract[65]	giv[65]	coref	20-5[183_65]
8-4	1177-1186	different	abstract[65]	giv[65]	_	_
8-5	1187-1193	scOHCs	abstract[65]	giv[65]	_	_
8-6	1194-1198	have	_	_	_	_
8-7	1199-1206	varying	abstract[66]	new[66]	_	_
8-8	1207-1217	capacities	abstract[66]	new[66]	_	_
8-9	1218-1220	to	abstract[66]	new[66]	_	_
8-10	1221-1229	activate	abstract[66]	new[66]	_	_
8-11	1230-1242	LXR-mediated	abstract[66]|abstract[67]	new[66]|giv[67]	_	_
8-12	1243-1256	transcription	abstract[66]|abstract[67]	new[66]|giv[67]	_	_
8-13	1257-1258	,	abstract[66]	new[66]	_	_
8-14	1259-1267	imposing	abstract[66]	new[66]	_	_
8-15	1268-1270	an	abstract[66]|abstract[68]	new[66]|new[68]	coref	11-35[92_68]
8-16	1271-1278	element	abstract[66]|abstract[68]	new[66]|new[68]	_	_
8-17	1279-1281	of	abstract[66]|abstract[68]	new[66]|new[68]	_	_
8-18	1282-1291	selective	abstract[66]|abstract[68]|abstract[69]	new[66]|new[68]|new[69]	_	_
8-19	1292-1302	modulation	abstract[66]|abstract[68]|abstract[69]	new[66]|new[68]|new[69]	_	_
8-20	1303-1307	onto	abstract[66]	new[66]	_	_
8-21	1308-1318	signalling	abstract[66]|abstract	new[66]|new	coref	14-12[139_0]
8-22	1319-1320	.	_	_	_	_

#Text=26-OHC ( commonly referred to as 27-OHC ) for example is the most abundant scOHC , but is a relatively weak LXR agonist .
9-1	1321-1327	26-OHC	substance[71]	new[71]	coref	9-12[73_71]
9-2	1328-1329	(	substance[71]	new[71]	_	_
9-3	1330-1338	commonly	substance[71]	new[71]	_	_
9-4	1339-1347	referred	substance[71]	new[71]	_	_
9-5	1348-1350	to	substance[71]	new[71]	_	_
9-6	1351-1353	as	substance[71]	new[71]	_	_
9-7	1354-1360	27-OHC	substance[71]|abstract	new[71]|new	_	_
9-8	1361-1362	)	substance[71]	new[71]	_	_
9-9	1363-1366	for	substance[71]	new[71]	_	_
9-10	1367-1374	example	substance[71]	new[71]	_	_
9-11	1375-1377	is	_	_	_	_
9-12	1378-1381	the	substance[73]|substance[74]	giv[73]|giv[74]	coref|coref	9-12[74_73]|10-8[0_74]
9-13	1382-1386	most	substance[73]|substance[74]	giv[73]|giv[74]	_	_
9-14	1387-1395	abundant	substance[73]|substance[74]	giv[73]|giv[74]	_	_
9-15	1396-1401	scOHC	substance[73]|substance[74]	giv[73]|giv[74]	_	_
9-16	1402-1403	,	substance[74]	giv[74]	_	_
9-17	1404-1407	but	substance[74]	giv[74]	_	_
9-18	1408-1410	is	substance[74]	giv[74]	_	_
9-19	1411-1412	a	substance[74]|abstract[76]	giv[74]|new[76]	_	_
9-20	1413-1423	relatively	substance[74]|abstract[76]	giv[74]|new[76]	_	_
9-21	1424-1428	weak	substance[74]|abstract[76]	giv[74]|new[76]	_	_
9-22	1429-1432	LXR	substance[74]|abstract|abstract[76]	giv[74]|giv|new[76]	coref	14-12
9-23	1433-1440	agonist	substance[74]|abstract[76]	giv[74]|new[76]	_	_
9-24	1441-1442	.	_	_	_	_

#Text=Moreover , there is little difference in scOHC concentrations between breast cancer subtypes .
10-1	1443-1451	Moreover	_	_	_	_
10-2	1452-1453	,	_	_	_	_
10-3	1454-1459	there	_	_	_	_
10-4	1460-1462	is	_	_	_	_
10-5	1463-1469	little	abstract[77]	new[77]	coref	21-23[201_77]
10-6	1470-1480	difference	abstract[77]	new[77]	_	_
10-7	1481-1483	in	abstract[77]	new[77]	_	_
10-8	1484-1489	scOHC	abstract[77]|substance|abstract[79]	new[77]|giv|giv[79]	coref|coref	14-3|14-3[135_79]
10-9	1490-1504	concentrations	abstract[77]|abstract[79]	new[77]|giv[79]	_	_
10-10	1505-1512	between	_	_	_	_
10-11	1513-1519	breast	abstract[80]|abstract[81]	new[80]|new[81]	coref|coref	13-25[0_80]|21-29[205_81]
10-12	1520-1526	cancer	abstract[80]|abstract[81]	new[80]|new[81]	_	_
10-13	1527-1535	subtypes	abstract[81]	new[81]	_	_
10-14	1536-1537	.	_	_	_	_

#Text=Transcriptional activity of the LXRs , like the other members of the Nuclear Receptor ( NR ) superfamily , is not just regulated by ligand bioavailability ; chromatin environment , cross-talk and competition for response element binding with other NRs , as well as cell- and tissue-type dependent expression of cofactors are also key mediators .
11-1	1538-1553	Transcriptional	abstract[82]	new[82]	_	_
11-2	1554-1562	activity	abstract[82]	new[82]	_	_
11-3	1563-1565	of	abstract[82]	new[82]	_	_
11-4	1566-1569	the	abstract[82]|abstract[83]	new[82]|new[83]	_	_
11-5	1570-1574	LXRs	abstract[82]|abstract[83]	new[82]|new[83]	_	_
11-6	1575-1576	,	abstract[82]	new[82]	_	_
11-7	1577-1581	like	abstract[82]	new[82]	_	_
11-8	1582-1585	the	abstract[82]|animal[84]	new[82]|new[84]	_	_
11-9	1586-1591	other	abstract[82]|animal[84]	new[82]|new[84]	_	_
11-10	1592-1599	members	abstract[82]|animal[84]	new[82]|new[84]	_	_
11-11	1600-1602	of	abstract[82]|animal[84]	new[82]|new[84]	_	_
11-12	1603-1606	the	abstract[82]|animal[84]|abstract[87]	new[82]|new[84]|new[87]	_	_
11-13	1607-1614	Nuclear	abstract[82]|animal[84]|substance[85]|abstract[87]	new[82]|new[84]|new[85]|new[87]	coref	13-39[122_85]
11-14	1615-1623	Receptor	abstract[82]|animal[84]|substance[85]|abstract[87]	new[82]|new[84]|new[85]|new[87]	_	_
11-15	1624-1625	(	abstract[82]|animal[84]|abstract[87]	new[82]|new[84]|new[87]	_	_
11-16	1626-1628	NR	abstract[82]|animal[84]|abstract|abstract[87]	new[82]|new[84]|new|new[87]	coref	22-14
11-17	1629-1630	)	abstract[82]|animal[84]|abstract[87]	new[82]|new[84]|new[87]	_	_
11-18	1631-1642	superfamily	abstract[82]|animal[84]|abstract[87]	new[82]|new[84]|new[87]	_	_
11-19	1643-1644	,	_	_	_	_
11-20	1645-1647	is	_	_	_	_
11-21	1648-1651	not	_	_	_	_
11-22	1652-1656	just	_	_	_	_
11-23	1657-1666	regulated	_	_	_	_
11-24	1667-1669	by	_	_	_	_
11-25	1670-1676	ligand	organization|abstract[89]	new|new[89]	coref|coref	13-65|22-4[208_89]
11-26	1677-1692	bioavailability	abstract[89]	new[89]	_	_
11-27	1693-1694	;	_	_	_	_
11-28	1695-1704	chromatin	substance	new	_	_
11-29	1705-1716	environment	_	_	_	_
11-30	1717-1718	,	_	_	_	_
11-31	1719-1729	cross-talk	_	_	_	_
11-32	1730-1733	and	_	_	_	_
11-33	1734-1745	competition	_	_	_	_
11-34	1746-1749	for	_	_	_	_
11-35	1750-1758	response	abstract|abstract[92]|abstract[93]	new|giv[92]|new[93]	coref	13-6[0_93]
11-36	1759-1766	element	abstract[92]|abstract[93]	giv[92]|new[93]	_	_
11-37	1767-1774	binding	abstract[93]	new[93]	_	_
11-38	1775-1779	with	abstract[93]	new[93]	_	_
11-39	1780-1785	other	abstract[93]|abstract[94]	new[93]|new[94]	_	_
11-40	1786-1789	NRs	abstract[93]|abstract[94]	new[93]|new[94]	_	_
11-41	1790-1791	,	_	_	_	_
11-42	1792-1794	as	_	_	_	_
11-43	1795-1799	well	_	_	_	_
11-44	1800-1802	as	_	_	_	_
11-45	1803-1808	cell-	_	_	_	_
11-46	1809-1812	and	_	_	_	_
11-47	1813-1824	tissue-type	_	_	_	_
11-48	1825-1834	dependent	_	_	_	_
11-49	1835-1845	expression	_	_	_	_
11-50	1846-1848	of	_	_	_	_
11-51	1849-1858	cofactors	abstract	new	_	_
11-52	1859-1862	are	_	_	_	_
11-53	1863-1867	also	_	_	_	_
11-54	1868-1871	key	person[96]	new[96]	_	_
11-55	1872-1881	mediators	person[96]	new[96]	_	_
11-56	1882-1883	.	_	_	_	_

#Text=For example , the expression of corepressors such as NCOR1 and NCOR2/SMRT determine how several cancers respond to nutritive ligands .
12-1	1884-1887	For	_	_	_	_
12-2	1888-1895	example	_	_	_	_
12-3	1896-1897	,	_	_	_	_
12-4	1898-1901	the	abstract[97]	new[97]	coref	22-14[214_97]
12-5	1902-1912	expression	abstract[97]	new[97]	_	_
12-6	1913-1915	of	abstract[97]	new[97]	_	_
12-7	1916-1928	corepressors	abstract[97]|abstract[98]	new[97]|new[98]	coref	13-11[108_98]
12-8	1929-1933	such	abstract[97]|abstract[98]	new[97]|new[98]	_	_
12-9	1934-1936	as	abstract[97]|abstract[98]	new[97]|new[98]	_	_
12-10	1937-1942	NCOR1	abstract[97]|abstract[98]|abstract|abstract[100]	new[97]|new[98]|new|new[100]	coref|coref	13-11[109_0]|13-11[110_100]
12-11	1943-1946	and	abstract[97]|abstract[98]|abstract[100]	new[97]|new[98]|new[100]	_	_
12-12	1947-1957	NCOR2/SMRT	abstract[97]|abstract[98]|abstract[100]|abstract	new[97]|new[98]|new[100]|new	_	_
12-13	1958-1967	determine	_	_	_	_
12-14	1968-1971	how	_	_	_	_
12-15	1972-1979	several	animal[102]	new[102]	_	_
12-16	1980-1987	cancers	animal[102]	new[102]	_	_
12-17	1988-1995	respond	_	_	_	_
12-18	1996-1998	to	_	_	_	_
12-19	1999-2008	nutritive	substance[103]	new[103]	_	_
12-20	2009-2016	ligands	substance[103]	new[103]	_	_
12-21	2017-2018	.	_	_	_	_

#Text=LXRA has a 100-fold higher binding affinity than LXRB for the corepressors NCOR1 and NCOR2 and deregulation of these corepressors allows prostate and bladder cancer cells to evade cancer suppressive signals of Vitamin D ( through repression of Vitamin D Receptor ( VDR ) ) and omega-3 fatty acids ( through repression of peroxisome proliferator-activated receptors ( PPARs ) ) by impairing sensitivity to ligand .
13-1	2019-2023	LXRA	abstract	giv	_	_
13-2	2024-2027	has	_	_	_	_
13-3	2028-2029	a	abstract[106]	new[106]	_	_
13-4	2030-2038	100-fold	abstract[106]	new[106]	_	_
13-5	2039-2045	higher	abstract[106]	new[106]	_	_
13-6	2046-2053	binding	abstract|abstract[106]	giv|new[106]	_	_
13-7	2054-2062	affinity	abstract[106]	new[106]	_	_
13-8	2063-2067	than	_	_	_	_
13-9	2068-2072	LXRB	abstract	giv	_	_
13-10	2073-2076	for	_	_	_	_
13-11	2077-2080	the	abstract[108]|abstract[109]|abstract[110]	giv[108]|giv[109]|giv[110]	coref	13-19[113_108]
13-12	2081-2093	corepressors	abstract[108]|abstract[109]|abstract[110]	giv[108]|giv[109]|giv[110]	_	_
13-13	2094-2099	NCOR1	abstract[109]|abstract[110]	giv[109]|giv[110]	_	_
13-14	2100-2103	and	abstract[110]	giv[110]	_	_
13-15	2104-2109	NCOR2	abstract[110]|abstract	giv[110]|new	_	_
13-16	2110-2113	and	_	_	_	_
13-17	2114-2126	deregulation	abstract[112]	new[112]	_	_
13-18	2127-2129	of	abstract[112]	new[112]	_	_
13-19	2130-2135	these	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
13-20	2136-2148	corepressors	abstract[112]|abstract[113]	new[112]|giv[113]	_	_
13-21	2149-2155	allows	_	_	_	_
13-22	2156-2164	prostate	animal|animal[116]	new|new[116]	coref	19-16[181_116]
13-23	2165-2168	and	animal[116]	new[116]	_	_
13-24	2169-2176	bladder	animal[116]	new[116]	_	_
13-25	2177-2183	cancer	abstract|animal[116]	giv|new[116]	coref	13-29
13-26	2184-2189	cells	animal[116]	new[116]	_	_
13-27	2190-2192	to	animal[116]	new[116]	_	_
13-28	2193-2198	evade	animal[116]	new[116]	_	_
13-29	2199-2205	cancer	animal[116]|abstract|abstract[118]	new[116]|giv|new[118]	coref	15-2
13-30	2206-2217	suppressive	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-31	2218-2225	signals	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-32	2226-2228	of	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-33	2229-2236	Vitamin	animal[116]|abstract[118]|substance[119]	new[116]|new[118]|new[119]	coref	13-39[121_119]
13-34	2237-2238	D	animal[116]|abstract[118]|substance[119]	new[116]|new[118]|new[119]	_	_
13-35	2239-2240	(	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-36	2241-2248	through	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-37	2249-2259	repression	animal[116]|abstract[118]|event[120]	new[116]|new[118]|new[120]	_	_
13-38	2260-2262	of	animal[116]|abstract[118]|event[120]	new[116]|new[118]|new[120]	_	_
13-39	2263-2270	Vitamin	animal[116]|abstract[118]|event[120]|substance[121]|substance[122]	new[116]|new[118]|new[120]|giv[121]|giv[122]	coref	17-2[165_122]
13-40	2271-2272	D	animal[116]|abstract[118]|event[120]|substance[121]|substance[122]	new[116]|new[118]|new[120]|giv[121]|giv[122]	_	_
13-41	2273-2281	Receptor	animal[116]|abstract[118]|event[120]|substance[122]	new[116]|new[118]|new[120]|giv[122]	_	_
13-42	2282-2283	(	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-43	2284-2287	VDR	animal[116]|abstract[118]|abstract	new[116]|new[118]|new	_	_
13-44	2288-2289	)	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-45	2290-2291	)	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-46	2292-2295	and	animal[116]|abstract[118]	new[116]|new[118]	_	_
13-47	2296-2303	omega-3	animal[116]|abstract[118]|abstract|substance[126]	new[116]|new[118]|new|giv[126]	_	_
13-48	2304-2309	fatty	animal[116]|abstract[118]|abstract|substance[126]	new[116]|new[118]|new|giv[126]	_	_
13-49	2310-2315	acids	animal[116]|abstract[118]|substance[126]	new[116]|new[118]|giv[126]	_	_
13-50	2316-2317	(	animal[116]	new[116]	_	_
13-51	2318-2325	through	animal[116]	new[116]	_	_
13-52	2326-2336	repression	animal[116]|event[127]	new[116]|new[127]	_	_
13-53	2337-2339	of	animal[116]|event[127]	new[116]|new[127]	_	_
13-54	2340-2350	peroxisome	animal[116]|event[127]|abstract|substance[130]	new[116]|new[127]|new|new[130]	_	_
13-55	2351-2373	proliferator-activated	animal[116]|event[127]|abstract|substance[130]	new[116]|new[127]|new|new[130]	_	_
13-56	2374-2383	receptors	animal[116]|event[127]|substance[130]	new[116]|new[127]|new[130]	_	_
13-57	2384-2385	(	_	_	_	_
13-58	2386-2391	PPARs	abstract	new	_	_
13-59	2392-2393	)	_	_	_	_
13-60	2394-2395	)	_	_	_	_
13-61	2396-2398	by	_	_	_	_
13-62	2399-2408	impairing	_	_	_	_
13-63	2409-2420	sensitivity	abstract[132]	new[132]	_	_
13-64	2421-2423	to	abstract[132]	new[132]	_	_
13-65	2424-2430	ligand	abstract[132]|organization	new[132]|giv	coref	21-4[194_0]
13-66	2431-2432	.	_	_	_	_

#Text=Simply measuring scOHC concentrations does not sufficiently determine their contributions to LXR signalling ; concentration and activation potential should be assessed in combination .
14-1	2433-2439	Simply	_	_	_	_
14-2	2440-2449	measuring	_	_	_	_
14-3	2450-2455	scOHC	substance|abstract[135]	giv|giv[135]	ana|coref	14-9[0_135]|22-4
14-4	2456-2470	concentrations	abstract[135]	giv[135]	_	_
14-5	2471-2475	does	_	_	_	_
14-6	2476-2479	not	_	_	_	_
14-7	2480-2492	sufficiently	_	_	_	_
14-8	2493-2502	determine	_	_	_	_
14-9	2503-2508	their	abstract|abstract[137]	giv|new[137]	_	_
14-10	2509-2522	contributions	abstract[137]	new[137]	_	_
14-11	2523-2525	to	abstract[137]	new[137]	_	_
14-12	2526-2529	LXR	abstract[137]|abstract|abstract[139]	new[137]|giv|giv[139]	coref|coref	16-4[152_139]|21-4
14-13	2530-2540	signalling	abstract[137]|abstract[139]	new[137]|giv[139]	_	_
14-14	2541-2542	;	_	_	_	_
14-15	2543-2556	concentration	abstract	new	_	_
14-16	2557-2560	and	_	_	_	_
14-17	2561-2571	activation	abstract|abstract[142]	new|new[142]	coref|coref	22-7|22-7[210_142]
14-18	2572-2581	potential	abstract[142]	new[142]	_	_
14-19	2582-2588	should	_	_	_	_
14-20	2589-2591	be	_	_	_	_
14-21	2592-2600	assessed	_	_	_	_
14-22	2601-2603	in	_	_	_	_
14-23	2604-2615	combination	_	_	_	_
14-24	2616-2617	.	_	_	_	_

#Text=In cancer , the function of the scOHC-LXR signalling axis appears site specific as both tumour suppressive and promoting roles have been described .
15-1	2618-2620	In	_	_	_	_
15-2	2621-2627	cancer	abstract	giv	coref	16-16[157_0]
15-3	2628-2629	,	_	_	_	_
15-4	2630-2633	the	abstract[144]	new[144]	_	_
15-5	2634-2642	function	abstract[144]	new[144]	_	_
15-6	2643-2645	of	abstract[144]	new[144]	_	_
15-7	2646-2649	the	abstract[144]|abstract[146]	new[144]|new[146]	_	_
15-8	2650-2659	scOHC-LXR	abstract[144]|abstract|abstract[146]	new[144]|new|new[146]	coref	16-4
15-9	2660-2670	signalling	abstract[144]|abstract[146]	new[144]|new[146]	_	_
15-10	2671-2675	axis	abstract[144]|abstract[146]	new[144]|new[146]	_	_
15-11	2676-2683	appears	_	_	_	_
15-12	2684-2688	site	object	new	_	_
15-13	2689-2697	specific	_	_	_	_
15-14	2698-2700	as	_	_	_	_
15-15	2701-2705	both	abstract[150]	new[150]	coref	23-37[228_150]
15-16	2706-2712	tumour	abstract|abstract[150]	new|new[150]	coref	21-29
15-17	2713-2724	suppressive	abstract|abstract[150]	new|new[150]	_	_
15-18	2725-2728	and	abstract[150]	new[150]	_	_
15-19	2729-2738	promoting	abstract[150]	new[150]	_	_
15-20	2739-2744	roles	abstract[150]	new[150]	_	_
15-21	2745-2749	have	_	_	_	_
15-22	2750-2754	been	_	_	_	_
15-23	2755-2764	described	_	_	_	_
15-24	2765-2766	.	_	_	_	_

#Text=For example , scOHC-LXR signalling impairs invasion and angiogenesis in melanoma and is anti-proliferative in lung cancer in vivo , as it is in almost every cancer cell line studied in vitro .
16-1	2767-2770	For	_	_	_	_
16-2	2771-2778	example	_	_	_	_
16-3	2779-2780	,	_	_	_	_
16-4	2781-2790	scOHC-LXR	abstract|abstract[152]	giv|giv[152]	coref|coref	23-29|23-29[226_152]
16-5	2791-2801	signalling	abstract[152]	giv[152]	_	_
16-6	2802-2809	impairs	_	_	_	_
16-7	2810-2818	invasion	event	new	_	_
16-8	2819-2822	and	_	_	_	_
16-9	2823-2835	angiogenesis	abstract[154]	new[154]	_	_
16-10	2836-2838	in	abstract[154]	new[154]	_	_
16-11	2839-2847	melanoma	abstract[154]|animal	new[154]|new	_	_
16-12	2848-2851	and	_	_	_	_
16-13	2852-2854	is	_	_	_	_
16-14	2855-2873	anti-proliferative	_	_	_	_
16-15	2874-2876	in	_	_	_	_
16-16	2877-2881	lung	object|abstract[157]	new|giv[157]	coref	16-27[0_157]
16-17	2882-2888	cancer	abstract[157]	giv[157]	_	_
16-18	2889-2891	in	abstract[157]	giv[157]	_	_
16-19	2892-2896	vivo	abstract[157]|abstract	giv[157]|new	ana	16-22
16-20	2897-2898	,	_	_	_	_
16-21	2899-2901	as	_	_	_	_
16-22	2902-2904	it	abstract	giv	coref	17-16
16-23	2905-2907	is	_	_	_	_
16-24	2908-2910	in	_	_	_	_
16-25	2911-2917	almost	abstract[162]	new[162]	_	_
16-26	2918-2923	every	abstract[162]	new[162]	_	_
16-27	2924-2930	cancer	abstract|abstract[162]	giv|new[162]	coref	17-2[168_0]
16-28	2931-2935	cell	object|abstract[162]	new|new[162]	_	_
16-29	2936-2940	line	abstract[162]	new[162]	_	_
16-30	2941-2948	studied	abstract[162]	new[162]	_	_
16-31	2949-2951	in	abstract[162]	new[162]	_	_
16-32	2952-2957	vitro	abstract[162]|abstract	new[162]|new	_	_
16-33	2958-2959	.	_	_	_	_

#Text=In Oestrogen Receptor ( ER)-positive Breast Cancer ( BCa ) however 26-OHC promotes growth in vivo via ER-alpha .
17-1	2960-2962	In	_	_	_	_
17-2	2963-2972	Oestrogen	substance|substance[165]|abstract[168]	new|giv[165]|giv[168]	appos|coref	17-9[0_168]|23-11[220_165]
17-3	2973-2981	Receptor	substance[165]|abstract[168]	giv[165]|giv[168]	_	_
17-4	2982-2983	(	abstract[168]	giv[168]	_	_
17-5	2984-2996	ER)-positive	person|abstract[168]	new|giv[168]	_	_
17-6	2997-3003	Breast	place|abstract[168]	new|giv[168]	_	_
17-7	3004-3010	Cancer	abstract[168]	giv[168]	_	_
17-8	3011-3012	(	_	_	_	_
17-9	3013-3016	BCa	abstract	giv	coref	18-2[174_0]
17-10	3017-3018	)	_	_	_	_
17-11	3019-3026	however	_	_	_	_
17-12	3027-3033	26-OHC	abstract	new	coref	19-1
17-13	3034-3042	promotes	_	_	_	_
17-14	3043-3049	growth	event	new	_	_
17-15	3050-3052	in	_	_	_	_
17-16	3053-3057	vivo	abstract	giv	_	_
17-17	3058-3061	via	_	_	_	_
17-18	3062-3070	ER-alpha	_	_	_	_
17-19	3071-3072	.	_	_	_	_

#Text=In ER-negative BCa
18-1	3073-3075	In	_	_	_	_
18-2	3076-3087	ER-negative	person|abstract[174]	new|giv[174]	coref	20-10[0_174]
18-3	3088-3091	BCa	abstract[174]	giv[174]	_	_

#Text=26-OHC drives the epithelial-to-mesenchymal transition and promotes colonization of metastatic sites in through mobilization of γδ-T cells .
19-1	3092-3098	26-OHC	abstract	giv	_	_
19-2	3099-3105	drives	_	_	_	_
19-3	3106-3109	the	event[176]	new[176]	_	_
19-4	3110-3135	epithelial-to-mesenchymal	event[176]	new[176]	_	_
19-5	3136-3146	transition	event[176]	new[176]	_	_
19-6	3147-3150	and	_	_	_	_
19-7	3151-3159	promotes	_	_	_	_
19-8	3160-3172	colonization	event[177]	new[177]	_	_
19-9	3173-3175	of	event[177]	new[177]	_	_
19-10	3176-3186	metastatic	event[177]|place[178]	new[177]|new[178]	_	_
19-11	3187-3192	sites	event[177]|place[178]	new[177]|new[178]	_	_
19-12	3193-3195	in	_	_	_	_
19-13	3196-3203	through	_	_	_	_
19-14	3204-3216	mobilization	event[179]	new[179]	_	_
19-15	3217-3219	of	event[179]	new[179]	_	_
19-16	3220-3224	γδ-T	event[179]|substance|animal[181]	new[179]|new|giv[181]	_	_
19-17	3225-3230	cells	event[179]|animal[181]	new[179]|giv[181]	_	_
19-18	3231-3232	.	_	_	_	_

#Text=Furthermore , concentrations of several scOHCs are altered in BCa relative to normal tissue , and 25-OHC is elevated in the circulation of BCa patients who have relapsed compared to those with primary disease .
20-1	3233-3244	Furthermore	_	_	_	_
20-2	3245-3246	,	_	_	_	_
20-3	3247-3261	concentrations	abstract[182]	new[182]	coref	21-26[203_182]
20-4	3262-3264	of	abstract[182]	new[182]	_	_
20-5	3265-3272	several	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
20-6	3273-3279	scOHCs	abstract[182]|abstract[183]	new[182]|giv[183]	_	_
20-7	3280-3283	are	_	_	_	_
20-8	3284-3291	altered	_	_	_	_
20-9	3292-3294	in	_	_	_	_
20-10	3295-3298	BCa	abstract	giv	coref	20-24
20-11	3299-3307	relative	_	_	_	_
20-12	3308-3310	to	_	_	_	_
20-13	3311-3317	normal	object[185]	giv[185]	_	_
20-14	3318-3324	tissue	object[185]	giv[185]	_	_
20-15	3325-3326	,	_	_	_	_
20-16	3327-3330	and	_	_	_	_
20-17	3331-3337	25-OHC	person	new	ana	20-31[190_0]
20-18	3338-3340	is	_	_	_	_
20-19	3341-3349	elevated	_	_	_	_
20-20	3350-3352	in	_	_	_	_
20-21	3353-3356	the	abstract[187]	new[187]	_	_
20-22	3357-3368	circulation	abstract[187]	new[187]	_	_
20-23	3369-3371	of	abstract[187]	new[187]	_	_
20-24	3372-3375	BCa	abstract[187]|abstract|person[189]	new[187]|giv|new[189]	coref|coref	21-10|23-49[0_189]
20-25	3376-3384	patients	abstract[187]|person[189]	new[187]|new[189]	_	_
20-26	3385-3388	who	abstract[187]|person[189]	new[187]|new[189]	_	_
20-27	3389-3393	have	abstract[187]|person[189]	new[187]|new[189]	_	_
20-28	3394-3402	relapsed	abstract[187]|person[189]	new[187]|new[189]	_	_
20-29	3403-3411	compared	_	_	_	_
20-30	3412-3414	to	_	_	_	_
20-31	3415-3420	those	person[190]	giv[190]	_	_
20-32	3421-3425	with	person[190]	giv[190]	_	_
20-33	3426-3433	primary	person[190]|abstract[191]	giv[190]|giv[191]	_	_
20-34	3434-3441	disease	person[190]|abstract[191]	giv[190]|giv[191]	_	_
20-35	3442-3443	.	_	_	_	_

#Text=We recently evaluated LXR ligand bio-availability in a small BCa cohort and found large inter tumoural heterogeneity in oxysterol content , but no difference in ligand concentrations between tumour subtypes .
21-1	3444-3446	We	person	acc	_	_
21-2	3447-3455	recently	_	_	_	_
21-3	3456-3465	evaluated	_	_	_	_
21-4	3466-3469	LXR	abstract|organization[194]|abstract[195]	giv|giv[194]|new[195]	coref	21-26[0_194]
21-5	3470-3476	ligand	organization[194]|abstract[195]	giv[194]|new[195]	_	_
21-6	3477-3493	bio-availability	abstract[195]	new[195]	_	_
21-7	3494-3496	in	_	_	_	_
21-8	3497-3498	a	abstract[197]	new[197]	_	_
21-9	3499-3504	small	abstract[197]	new[197]	_	_
21-10	3505-3508	BCa	abstract|abstract[197]	giv|new[197]	coref	22-18
21-11	3509-3515	cohort	abstract[197]	new[197]	_	_
21-12	3516-3519	and	_	_	_	_
21-13	3520-3525	found	_	_	_	_
21-14	3526-3531	large	abstract[198]	new[198]	_	_
21-15	3532-3537	inter	abstract[198]	new[198]	_	_
21-16	3538-3546	tumoural	abstract[198]	new[198]	_	_
21-17	3547-3560	heterogeneity	abstract[198]	new[198]	_	_
21-18	3561-3563	in	abstract[198]	new[198]	_	_
21-19	3564-3573	oxysterol	abstract[198]|abstract|abstract[200]	new[198]|new|new[200]	_	_
21-20	3574-3581	content	abstract[198]|abstract[200]	new[198]|new[200]	_	_
21-21	3582-3583	,	_	_	_	_
21-22	3584-3587	but	_	_	_	_
21-23	3588-3590	no	abstract[201]	giv[201]	_	_
21-24	3591-3601	difference	abstract[201]	giv[201]	_	_
21-25	3602-3604	in	abstract[201]	giv[201]	_	_
21-26	3605-3611	ligand	abstract[201]|organization|abstract[203]	giv[201]|giv|giv[203]	_	_
21-27	3612-3626	concentrations	abstract[201]|abstract[203]	giv[201]|giv[203]	_	_
21-28	3627-3634	between	abstract[201]	giv[201]	_	_
21-29	3635-3641	tumour	abstract[201]|abstract|abstract[205]	giv[201]|giv|giv[205]	coref	22-18[216_205]
21-30	3642-3650	subtypes	abstract[201]|abstract[205]	giv[201]|giv[205]	_	_
21-31	3651-3652	.	_	_	_	_

#Text=Systematic evaluation of scOHC bioavailability and activation potential , coupled with analysis of NR cofactor expression between BCa subtypes has not been performed previously .
22-1	3653-3663	Systematic	abstract[206]	new[206]	_	_
22-2	3664-3674	evaluation	abstract[206]	new[206]	_	_
22-3	3675-3677	of	abstract[206]	new[206]	_	_
22-4	3678-3683	scOHC	abstract[206]|substance|abstract[208]	new[206]|giv|giv[208]	_	_
22-5	3684-3699	bioavailability	abstract[206]|abstract[208]	new[206]|giv[208]	_	_
22-6	3700-3703	and	abstract[206]	new[206]	_	_
22-7	3704-3714	activation	abstract[206]|abstract|abstract[210]	new[206]|giv|giv[210]	_	_
22-8	3715-3724	potential	abstract[206]|abstract[210]	new[206]|giv[210]	_	_
22-9	3725-3726	,	abstract[206]	new[206]	_	_
22-10	3727-3734	coupled	abstract[206]	new[206]	_	_
22-11	3735-3739	with	abstract[206]	new[206]	_	_
22-12	3740-3748	analysis	abstract[206]|abstract[211]	new[206]|new[211]	_	_
22-13	3749-3751	of	abstract[206]|abstract[211]	new[206]|new[211]	_	_
22-14	3752-3754	NR	abstract[206]|abstract[211]|abstract|abstract[214]	new[206]|new[211]|giv|giv[214]	_	_
22-15	3755-3763	cofactor	abstract[206]|abstract[211]|person|abstract[214]	new[206]|new[211]|new|giv[214]	_	_
22-16	3764-3774	expression	abstract[206]|abstract[211]|abstract[214]	new[206]|new[211]|giv[214]	_	_
22-17	3775-3782	between	abstract[206]|abstract[211]|abstract[214]	new[206]|new[211]|giv[214]	_	_
22-18	3783-3786	BCa	abstract[206]|abstract[211]|abstract[214]|abstract|abstract[216]	new[206]|new[211]|giv[214]|giv|giv[216]	coref|coref	23-9|23-24[224_216]
22-19	3787-3795	subtypes	abstract[206]|abstract[211]|abstract[214]|abstract[216]	new[206]|new[211]|giv[214]|giv[216]	_	_
22-20	3796-3799	has	_	_	_	_
22-21	3800-3803	not	_	_	_	_
22-22	3804-3808	been	_	_	_	_
22-23	3809-3818	performed	_	_	_	_
22-24	3819-3829	previously	_	_	_	_
22-25	3830-3831	.	_	_	_	_

#Text=Given the prognostic and therapeutic value of stratifying BCa by hormone receptor status , further delineation of the pathways that are altered between these subtypes , such as scOHC-LXR signalling , may help advance understanding about the emerging roles of cholesterol metabolism in cancer and improve outcomes for patients .
23-1	3832-3837	Given	_	_	_	_
23-2	3838-3841	the	abstract[217]	new[217]	_	_
23-3	3842-3852	prognostic	abstract[217]	new[217]	_	_
23-4	3853-3856	and	abstract[217]	new[217]	_	_
23-5	3857-3868	therapeutic	abstract[217]	new[217]	_	_
23-6	3869-3874	value	abstract[217]	new[217]	_	_
23-7	3875-3877	of	abstract[217]	new[217]	_	_
23-8	3878-3889	stratifying	abstract[217]	new[217]	_	_
23-9	3890-3893	BCa	abstract[217]|abstract	new[217]|giv	coref	23-44
23-10	3894-3896	by	abstract[217]	new[217]	_	_
23-11	3897-3904	hormone	abstract[217]|substance|substance[220]|abstract[221]	new[217]|new|giv[220]|giv[221]	_	_
23-12	3905-3913	receptor	abstract[217]|substance[220]|abstract[221]	new[217]|giv[220]|giv[221]	_	_
23-13	3914-3920	status	abstract[217]|abstract[221]	new[217]|giv[221]	_	_
23-14	3921-3922	,	_	_	_	_
23-15	3923-3930	further	substance[222]	new[222]	_	_
23-16	3931-3942	delineation	substance[222]	new[222]	_	_
23-17	3943-3945	of	substance[222]	new[222]	_	_
23-18	3946-3949	the	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-19	3950-3958	pathways	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-20	3959-3963	that	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-21	3964-3967	are	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-22	3968-3975	altered	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-23	3976-3983	between	substance[222]|abstract[223]	new[222]|new[223]	_	_
23-24	3984-3989	these	substance[222]|abstract[223]|abstract[224]	new[222]|new[223]|giv[224]	_	_
23-25	3990-3998	subtypes	substance[222]|abstract[223]|abstract[224]	new[222]|new[223]|giv[224]	_	_
23-26	3999-4000	,	substance[222]	new[222]	_	_
23-27	4001-4005	such	substance[222]	new[222]	_	_
23-28	4006-4008	as	substance[222]	new[222]	_	_
23-29	4009-4018	scOHC-LXR	substance[222]|abstract|abstract[226]	new[222]|giv|giv[226]	_	_
23-30	4019-4029	signalling	substance[222]|abstract[226]	new[222]|giv[226]	_	_
23-31	4030-4031	,	_	_	_	_
23-32	4032-4035	may	_	_	_	_
23-33	4036-4040	help	_	_	_	_
23-34	4041-4048	advance	_	_	_	_
23-35	4049-4062	understanding	abstract[227]	new[227]	_	_
23-36	4063-4068	about	abstract[227]	new[227]	_	_
23-37	4069-4072	the	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
23-38	4073-4081	emerging	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
23-39	4082-4087	roles	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
23-40	4088-4090	of	abstract[227]|abstract[228]	new[227]|giv[228]	_	_
23-41	4091-4102	cholesterol	abstract[227]|abstract[228]|substance|abstract[230]	new[227]|giv[228]|giv|giv[230]	_	_
23-42	4103-4113	metabolism	abstract[227]|abstract[228]|abstract[230]	new[227]|giv[228]|giv[230]	_	_
23-43	4114-4116	in	abstract[227]|abstract[228]|abstract[230]	new[227]|giv[228]|giv[230]	_	_
23-44	4117-4123	cancer	abstract[227]|abstract[228]|abstract[230]|abstract	new[227]|giv[228]|giv[230]|giv	_	_
23-45	4124-4127	and	_	_	_	_
23-46	4128-4135	improve	_	_	_	_
23-47	4136-4144	outcomes	abstract	new	_	_
23-48	4145-4148	for	_	_	_	_
23-49	4149-4157	patients	person	giv	_	_
23-50	4158-4159	.	_	_	_	_
